Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | ROS1 | P08922 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417669 | 1.00 | PNMT (0.42) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL204312 | 0.83 | SRD5A1 (0.44) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL5366924 | 0.82 | ASIC3 (0.46) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL4523516 | 0.82 | PNMT (0.46) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL29790845 | 0.82 | PNMT (0.46) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL8169279 | 0.74 | METAP1 (0.44) | METAP1LMNAMAPTTDP2AHR | |
| SCHEMBL17802101 | 0.74 | METAP1 (0.49) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL30016060 | 0.74 | METAP1 (0.49) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL23705368 | 0.74 | METAP1 (0.44) | PNMTASIC3METAP1LMNAMAPT | |
| SCHEMBL3174866 | 0.74 | PARP10 (0.43) | METAP1TDP2AHRCMA1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2005077927-A1 | ONE POT SYNTHESIS OF CITALOPRAM FROM 5-CYANOPHTHALIDE | JUBILANT ORGANOSYS LIMITED (IN) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077891-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005066185-A1 | PROCESS FOR PREPARING 5-SUBSTITUTED -1-(4-FLUOROPHENYL) -1,3-DIHYDROISOBENZOFURANS | JUBILANT ORGANOSYS LIMITED (IN) | 2005-07-21 | — | — | WO | disclosed |
| EP-1534654-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020425-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED-1-(4-FLUOROPHENYL)-1,3-DIHYDROISOBENZOFURANS | JUBILANT ORGANOSYS LTD. (IN) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004014821-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2004-02-19 | — | — | WO | disclosed |
| CN-1468100-A | pharmaceutical compositions and methods of use | ���Ͽع�����˾ | 2004-01-14 | — | — | CN | disclosed |
| CN-1452486-A | pharmaceutical compositions and methods of use | TARGACEPT INC (US) | 2003-10-29 | — | — | CN | disclosed |
| EP-1246813-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049672-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | PNMT 19/4885ASIC3 3214/4885METAP1 2239/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | PNMT 436/4885ASIC3 2774/4885METAP1 1445/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | PNMT 99/4885ASIC3 3862/4885METAP1 790/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | PNMT 4342/4885ASIC3 3867/4885METAP1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.